by Peter Ciszewski | Oct 26, 2021
Avanish Vellanki, Cofounder and CEO at Rain Therapeutics, discusses the role of p53 and MDM2 in cancers like liposarcoma. As Mr. Vellanki explains, p53 regulates the cell cycle, and in that role is essential for tumor suppression. MDM2 is a crucial regulator of...
by Peter Ciszewski | Oct 25, 2021
Daniel DeAngelo, MD, PhD, Chief, Division of Leukemia, Dana-Farber Cancer Institute, discusses treatment options available for systemic mastocytosis (SM). SM is a rare, hematologic disorder most often caused by a mutation in the KIT D816V gene. The disorder is...
by Peter Ciszewski | Oct 25, 2021
Evanthia Bernitsas, MD, of the Department of Neurology at Wayne State University School of Medicine, gives an overview of neuromyelitis optica spectrum disorder (NMOSD) and discusses how the disease affects certain race populations differently. As Dr. Bernitsas...
by Peter Ciszewski | Oct 25, 2021
Nina Shah, MD, Hematologist from the University of California, San Francisco, discusses preclinical data demonstrating that a subset of human natural killer (NK) cells that lack expression of FcεRIγ (g-NK cells) enhance the efficacy of monoclonal antibody...
by Peter Ciszewski | Oct 24, 2021
Lauren Pinter-Brown, MD, Clinical Professor of Hematology/Oncology, University of California Irvine and Director of the Cutaneous Lymphoma Foundation, discusses what physicians should know about cutaneous T-cell lymphoma (CTCL). CTCL belongs to the non-Hodgkin...
